A collision occurred on the ramp of Missouri Route 367 to Interstate 270 in north St. Louis County, resulting in serious ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The United States is seeing a second peak in flu cases this season. After doctor’s office visits for flu dipped early this ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

"More broadly on LLY, we continue to see the company as optimally positioned in an incretin market that we see growing to ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...